443998-65-0

Basic information

• Product Name: 1-BOC-4-(4-BROMO-PHENYLAMINO)-PIPERIDINE
• Synonyms: 4-(4-BROMO-PHENYLAMINO)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-BOC-4-(4-BROMO-PHENYLAMINO)-PIPERIDINE;tert-butyl 4-(4-bromoanilino)piperidine-1-carboxylate;TERT-BUTYL 4-(4-BROMOPHENYLAMINO)-PIPERIDINE-1-CARBOXYLATE
• CAS NO: 443998-65-0
• Molecular Formula: C₁₆H₂₃BrN₂O₂
• Molecular Weight: 355.27
• Mol File: 443998-65-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 439.1±40.0 °C(Predicted)
• Appearance: /
• Density: 1.336±0.06 g/cm3(Predicted)
• PKA: 4.18±0.20(Predicted)
• CAS DataBase Reference: 1-BOC-4-(4-BROMO-PHENYLAMINO)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-(4-BROMO-PHENYLAMINO)-PIPERIDINE(443998-65-0)
• EPA Substance Registry System: 1-BOC-4-(4-BROMO-PHENYLAMINO)-PIPERIDINE(443998-65-0)

Safety Data

• Hazardous Substances Data: 443998-65-0(Hazardous Substances Data)

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 106-40-1 4-bromo-aniline 

Downstream Products

• 1534378-15-8 tert-butyl 4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)amino)piperidine-1-carboxylate 
• 1350809-08-3 C₂₄H₂₈BrN₃O₂ 
• 1350809-06-1 C₂₃H₂₈BrClN₂O₂ 
• 1350809-07-2 C₂₄H₃₁BrN₂O₃ 
• 1350809-05-0 C₂₃H₂₈BrClN₂O₂ 
• 1350809-04-9 C₂₃H₂₈BrClN₂O₂ 
• 501446-70-4 C₂₃H₂₉BrN₂O₂ 
• 1350809-23-2 C₁₉H₂₀BrN₃ 
• 1350809-22-1 C₁₉H₂₃BrN₂O 
• 1350809-21-0 C₁₈H₂₀BrClN₂ 
• 1350809-20-9 C₁₈H₂₀BrClN₂ 
• 1350809-19-6 C₁₈H₂₀BrClN₂ 
• 501446-71-5 C₁₈H₂₁BrN₂ 
• 947607-17-2 4-(4-pyrimidin-2-yl-phenylamino)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, Q2, L1 and n are as defined herein. The compounds have antifungal properties and are useful in the treatment of fungal infections, including infections that are resistant to conventions anti-fungal agents. Q1 is selected from: (Formulae Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij and Ik) wherein * indicates the point of attachment to L1.

Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonists

Structural features of the substituted 4-piperidinyl urea analogs 1, responsible for the H3 antagonist activity, have been identified. Structure-activity relationship of the H3 receptor affinity, hERG ion channel inhibitory activity and their separation is described. Preliminary pharmacokinetic evaluation of the compounds of the series is addressed.

Cyclic amine compounds and pharmaceutical composition containing the same

A cyclic amine compound represented by the following general formula (1): wherein, R1, R2 and R3 each independently represent a hydrogen atom or an alkoxy group;W1 and W2 each independently represent N or CH;X represents O, NR4, CONR4 or NR4CO;R4 represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; andl, m and n each represents a number of 0 or 1, a salt thereof and a hydrate thereof are provided. These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.